Published in Eur J Pharm Sci on April 18, 2005
Plasma clearance of bacteriophage Qbeta particles as a function of surface charge. J Am Chem Soc (2008) 1.41
Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine (2007) 1.21
Nanoparticles for brain drug delivery. ISRN Biochem (2013) 0.99
Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage (2010) 0.95
Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation. Int J Pharm (2010) 0.90
Effects on interactions of oppositely charged phospholipid vesicles of covalent attachment of polyethylene glycol oligomers to their surfaces: adhesion, hemifusion, full fusion and "endocytosis". J Membr Biol (2008) 0.79
Agile delivery of protein therapeutics to CNS. J Control Release (2014) 0.79
NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY. Nano Life (2013) 0.75
Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem (2003) 2.60
Structure-immunogenicity relationships of therapeutic proteins. Pharm Res (2004) 2.39
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages. J Clin Pharmacol (2014) 1.99
Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn (2008) 1.95
Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res (2006) 1.84
A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood (2003) 1.74
The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol (2010) 1.71
Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov (2006) 1.52
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet (2011) 1.51
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Disease system analysis: basic disease progression models in degenerative disease. Pharm Res (2005) 1.45
Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug Chem (2006) 1.37
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn (2006) 1.35
Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity? Pharm Res (2003) 1.34
Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet (2009) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci (2006) 1.32
Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res (2005) 1.32
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
What is the right dose for children? Br J Clin Pharmacol (2010) 1.24
Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet (2002) 1.23
The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol (2010) 1.20
How to screen non-viral gene delivery systems in vitro? J Control Release (2011) 1.17
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci (2010) 1.16
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit (2009) 1.12
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther (2004) 1.12
Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinet (2007) 1.10
Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet (2012) 1.10
Endosomal escape of polymeric gene delivery complexes is not always enhanced by polymers buffering at low pH. Biomacromolecules (2004) 1.09
Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes. Exp Hematol (2004) 1.08
The nuclear pore complex: the gateway to successful nonviral gene delivery. Pharm Res (2006) 1.07
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today (2008) 1.07
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res (2007) 1.05
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther (2005) 1.05
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet (2009) 1.04
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses. PLoS One (2011) 1.04
Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol (2011) 1.03
Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release (2012) 1.02
Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem (2002) 1.02
Self-assembly of recombinant amphiphilic oligopeptides into vesicles. Biomacromolecules (2007) 1.02
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther (2007) 1.02
Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol (2014) 1.02
Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol (2010) 1.00
A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res (2013) 1.00
Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions. Br J Clin Pharmacol (2013) 0.99
Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm (2011) 0.99
Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res (2010) 0.98
Evidence-based morphine dosing for postoperative neonates and infants. Clin Pharmacokinet (2014) 0.98
Polymer side-chain degradation as a tool to control the destabilization of polyplexes. Pharm Res (2004) 0.98
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn (2012) 0.97
Poly(3-guanidinopropyl methacrylate): a novel cationic polymer for gene delivery. Bioconjug Chem (2004) 0.97
Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation. Br J Clin Pharmacol (2013) 0.97
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography. Epilepsia (2008) 0.96
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn (2012) 0.96
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet (2012) 0.96
Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol (2002) 0.96
Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant (2012) 0.95
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res (2007) 0.95
Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet (2013) 0.95
N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine (2006) 0.94
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res (2012) 0.94
A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem (2003) 0.94
Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres. Pharm Res (2011) 0.94
Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet (2011) 0.94
Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv (2005) 0.94
Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci (2011) 0.94
Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol (2005) 0.94
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol (2004) 0.94
Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet (2010) 0.93
Coping with time scales in disease systems analysis: application to bone remodeling. J Pharmacokinet Pharmacodyn (2011) 0.93
Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology (2006) 0.93
Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet (2010) 0.93
Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother (2010) 0.93
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res (2012) 0.92
Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci (2011) 0.92
Liposomes and ISCOMs. Vaccine (2003) 0.92
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients. Eur J Clin Pharmacol (2007) 0.91
Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos (2011) 0.91
Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci (2004) 0.91
CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. Acta Neuropathol Commun (2014) 0.91
Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol (2014) 0.91
Stabilization of peptide vesicles by introducing inter-peptide disulfide bonds. Pharm Res (2009) 0.90
Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. Vaccine (2003) 0.90
Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target (2004) 0.89
Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine (2003) 0.89
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn (2013) 0.89
Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit (2012) 0.89
Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur J Pharm Sci (2011) 0.88
Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov Today (2012) 0.88
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Eur J Pharm Sci (2008) 0.88
Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J (2012) 0.88
Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying. Eur J Pharm Sci (2005) 0.87
Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochim Biophys Acta (2002) 0.87
A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. Exp Eye Res (2011) 0.87